Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQ-B211 + docetaxel
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
TQ-B211 + docetaxel is a combination therapy consisting of TQ-B211, a trastuzumab biosimilar developed by Chia Tai Tianqing Pharmaceutical Group, and the chemotherapy agent docetaxel. TQ-B211 is a recombinant humanized monoclonal antibody that targets the extracellular domain of HER2 (ERBB2), inhibiting its signaling and mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Docetaxel is a taxane-class chemotherapeutic that disrupts microtubule function, inhibiting cell division. This combination is primarily investigated for first-line treatment of HER2-positive metastatic breast cancer and has also been studied in neoadjuvant settings for early-stage disease. Clinical studies have shown comparable efficacy, safety, and immunogenicity between this regimen and reference trastuzumab (Herceptin) plus docetaxel[5][7][8].
- Other names
- trastuzumab biosimilar + docetaxelTQB211 + docetaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TQ-B211 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQ-B211 + docetaxel.